Nicholas F Larusso

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8744234/publications.pdf

Version: 2024-02-01

243	23,670	5574 82	8866 145
papers	citations	h-index	g-index

251	251	251	17909
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Induced Pluripotent Stem Cells From Subjects With Primary Sclerosing Cholangitis Develop a Senescence Phenotype Following Biliary Differentiation. Hepatology Communications, 2022, 6, 345-360.	4.3	12
2	Polycystic Liver Disease: Advances in Understanding and Treatment. Annual Review of Pathology: Mechanisms of Disease, 2022, 17, 251-269.	22.4	15
3	Highâ€Resolution Exposomics and Metabolomics Reveals Specific Associations in Cholestatic Liver Diseases. Hepatology Communications, 2022, 6, 965-979.	4.3	11
4	Autophagy promotes hepatic cystogenesis in polycystic liver disease by depletion of cholangiocyte ciliogenic proteins. Hepatology, 2022, 75, 1110-1122.	7.3	7
5	Comparative Performance of Quantitative and Qualitative Magnetic Resonance Imaging Metrics in Primary Sclerosing Cholangitis. , 2022, 1, 287-295.		1
6	Cellular senescence in the cholangiopathies: a driver of immunopathology and a novel therapeutic target. Seminars in Immunopathology, 2022, 44, 527-544.	6.1	16
7	Long non-coding RNA ACTA2-AS1 promotes ductular reaction by interacting with the p300/ELK1 complex. Journal of Hepatology, 2022, 76, 921-933.	3.7	15
8	Cellular senescence in the cholangiopathies. Current Opinion in Gastroenterology, 2022, 38, 121-127.	2.3	9
9	Portal fibroblasts: A renewable source of liver myofibroblasts. Hepatology, 2022, 76, 1240-1242.	7.3	1
10	DNA methylation profile of liver tissue in end-stage cholestatic liver disease. Epigenomics, 2022, 14, 481-497.	2.1	2
11	Genetics, pathobiology and therapeutic opportunities of polycystic liver disease. Nature Reviews Gastroenterology and Hepatology, 2022, 19, 585-604.	17.8	15
12	Bile Acid Profiles in Primary Sclerosing Cholangitis and Their Ability to Predict Hepatic Decompensation. Hepatology, 2021, 74, 281-295.	7.3	40
13	Targeting UBC9-mediated protein hyper-SUMOylation in cystic cholangiocytes halts polycystic liver disease in experimental models. Journal of Hepatology, 2021, 74, 394-406.	3.7	14
14	Early Cholangiocarcinoma Detection With Magnetic Resonance Imaging Versus Ultrasound in Primary Sclerosing Cholangitis. Hepatology, 2021, 73, 1868-1881.	7.3	25
15	An aged immune system drives senescence and ageing of solid organs. Nature, 2021, 594, 100-105.	27.8	368
16	Genetic or pharmacological reduction of cholangiocyte senescence improves inflammation and fibrosis in the Mdr2Âmouse. JHEP Reports, 2021, 3, 100250.	4.9	17
17	Immunotherapy-based targeting of MSLN ⁺ activated portal fibroblasts is a strategy for treatment of cholestatic liver fibrosis. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	11
18	Autophagy-mediated reduction of miR-345 contributes to hepatic cystogenesis in polycystic liver disease. JHEP Reports, 2021, 3, 100345.	4.9	4

#	Article	IF	Citations
19	Liver Stiffness Measured by Either Magnetic Resonance or Transient Elastography Is Associated With Liver Fibrosis and Is an Independent Predictor of Outcomes Among Patients With Primary Biliary Cholangitis. Journal of Clinical Gastroenterology, 2021, 55, 449-457.	2.2	34
20	Primary Sclerosing Cholangitis Risk Estimate Tool (PREsTo) Predicts Outcomes of the Disease: A Derivation and Validation Study Using Machine Learning. Hepatology, 2020, 71, 214-224.	7.3	90
21	Changes in Liver Stiffness, Measured by Magnetic Resonance Elastography, Associated With Hepatic Decompensation in Patients With Primary Sclerosing Cholangitis. Clinical Gastroenterology and Hepatology, 2020, 18, 1576-1583.e1.	4.4	30
22	The Spectrum of Reactive Cholangiocytes in Primary Sclerosing Cholangitis. Hepatology, 2020, 71, 741-748.	7.3	41
23	Pansomatostatin Agonist Pasireotide Long-Acting Release for Patients with Autosomal Dominant Polycystic Kidney or Liver Disease with Severe Liver Involvement. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 1267-1278.	4.5	24
24	Polarized human cholangiocytes release distinct populations of apical and basolateral small extracellular vesicles. Molecular Biology of the Cell, 2020, 31, 2463-2474.	2.1	11
25	Proteostasis disturbances and endoplasmic reticulum stress contribute to polycystic liver disease: New therapeutic targets. Liver International, 2020, 40, 1670-1685.	3.9	22
26	Senescent cholangiocytes release extracellular vesicles that alter target cell phenotype via the epidermal growth factor receptor. Liver International, 2020, 40, 2455-2468.	3.9	20
27	A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis. Journal of Hepatology, 2020, 73, 94-101.	3.7	111
28	An update on primary sclerosing cholangitis epidemiology, outcomes and quantification of alkaline phosphatase variability in a population-based cohort. Journal of Gastroenterology, 2020, 55, 523-532.	5.1	22
29	Ileo-colonic delivery of conjugated bile acids improves glucose homeostasis via colonic GLP-1-producing enteroendocrine cells in human obesity and diabetes. EBioMedicine, 2020, 55, 102759.	6.1	43
30	Bacterial Cholangitis in Autosomal Dominant Polycystic Kidney and Liver Disease. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2019, 3, 149-159.	2.4	4
31	The transcription factor ETS1 promotes apoptosis resistance of senescent cholangiocytes by epigenetically up-regulating the apoptosis suppressor BCL2L1. Journal of Biological Chemistry, 2019, 294, 18698-18713.	3.4	22
32	Efficacy and safety of curcumin in primary sclerosing cholangitis: an open label pilot study. Scandinavian Journal of Gastroenterology, 2019, 54, 633-639.	1.5	23
33	Cholangiocyte pathobiology. Nature Reviews Gastroenterology and Hepatology, 2019, 16, 269-281.	17.8	285
34	Pancreatobiliary Ductal Dilatation: Unique Pathobiological Processes and Endoscopic Revelations. Gastroenterology, 2019, 156, 876-878.	1.3	2
35	Spontaneous DNA damage to the nuclear genome promotes senescence, redox imbalance and aging. Redox Biology, 2018, 17, 259-273.	9.0	103
36	Combination of a Histone Deacetylase 6 Inhibitor and a Somatostatin Receptor Agonist Synergistically Reduces Hepatorenal Cystogenesis in an Animal Model of Polycystic Liver Disease. American Journal of Pathology, 2018, 188, 981-994.	3.8	16

#	Article	IF	Citations
37	MicroRNA (miR)â€433 and miRâ€22 dysregulations induce histoneâ€deacetylaseâ€6 overexpression and ciliary loss in cholangiocarcinoma. Hepatology, 2018, 68, 561-573.	7.3	54
38	Pathobiology of biliary epithelia. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 1220-1231.	3.8	29
39	A 59-Year-Old Man With New Jaundice. Gastroenterology, 2018, 154, 2035-2036.	1.3	1
40	Cholangiocyte autophagy contributes to hepatic cystogenesis in polycystic liver disease and represents a potential therapeutic target. Hepatology, 2018, 67, 1088-1108.	7.3	29
41	MicroRNAâ€506 promotes primary biliary cholangitisâ€“like features in cholangiocytes and immune activation. Hepatology, 2018, 67, 1420-1440.	7.3	72
42	Polycystic liver disease: The interplay of genes causative for hepatic and renal cystogenesis. Hepatology, 2018, 67, 2462-2464.	7.3	13
43	Milder disease stage in patients with primary biliary cholangitis over a 44â€year period: A changing natural history. Hepatology, 2018, 67, 1920-1930.	7.3	55
44	Targeting senescent cholangiocytes and activated fibroblasts with Bâ€cell lymphomaâ€extra large inhibitors ameliorates fibrosis in multidrug resistance 2 gene knockout (Mdr2â^'/â^') mice. Hepatology, 2018, 67, 247-259.	7.3	99
45	Hemobilia: Etiology, diagnosis, and treatment. Liver Research, 2018, 2, 200-208.	1.4	46
46	Metabolomic Profiling of Portal Blood and Bile Reveals Metabolic Signatures of Primary Sclerosing Cholangitis. International Journal of Molecular Sciences, 2018, 19, 3188.	4.1	28
47	Macrophages contribute to the pathogenesis of sclerosing cholangitis in mice. Journal of Hepatology, 2018, 69, 676-686.	3.7	119
48	Physiology of Cholngiocytes. , 2018, , 1003-1023.		2
49	Cholangiocytes in health and disease: From basic science to novel treatments. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 1217-1219.	3.8	2
50	ETS Proto-oncogene 1 Transcriptionally Up-regulates the Cholangiocyte Senescence-associated Protein Cyclin-dependent Kinase Inhibitor 2A. Journal of Biological Chemistry, 2017, 292, 4833-4846.	3.4	26
51	B-type natriuretic peptide overexpression ameliorates hepatorenal fibrocystic disease inÂaÂratÂmodel of polycystic kidney disease. Kidney International, 2017, 92, 657-668.	5.2	7
52	Doublecortin domain containing protein 2 (DCDC2) genetic variants in primary sclerosing cholangitis. Journal of Hepatology, 2017, 67, 651-652.	3.7	1
53	TGR5 contributes to hepatic cystogenesis in rodents with polycystic liver diseases through cyclic adenosine monophosphate/Gl±s signaling. Hepatology, 2017, 66, 1197-1218.	7.3	46
54	Epigenetics in the Primary Biliary Cholangitis and Primary Sclerosing Cholangitis. Seminars in Liver Disease, 2017, 37, 159-174.	3.6	26

#	Article	IF	Citations
55	Role of the Intestinal Microbiome in Cholestatic Liver Disease. Digestive Diseases, 2017, 35, 166-168.	1.9	14
56	Cholangiocytes and the environment in primary sclerosing cholangitis: where is the link?. Gut, 2017, 66, 1873-1877.	12.1	37
57	Development and characterization of cholangioids from normal and diseased human cholangiocytes as an in vitro model to study primary sclerosing cholangitis. Laboratory Investigation, 2017, 97, 1385-1396.	3.7	39
58	Charcoal hemoperfusion in the treatment of medically refractory pruritus in cholestatic liver disease. Hepatology International, 2017, 11, 384-389.	4.2	11
59	Primary Cilia in Tumor Biology: The Primary Cilium as a Therapeutic Target in Cholangiocarcinoma. Current Drug Targets, 2017, 18, 958-963.	2.1	29
60	Therapeutic Targets in Polycystic Liver Disease. Current Drug Targets, 2017, 18, 950-957.	2.1	35
61	Cholangiocyte Biology. , 2017, , 83-97.		1
62	Performance of magnetic resonance elastography in primary sclerosing cholangitis. Journal of Gastroenterology and Hepatology (Australia), 2016, 31, 1184-1190.	2.8	83
63	Primary Sclerosing Cholangitis. New England Journal of Medicine, 2016, 375, 2500-2502.	27.0	48
64	Absence of the intestinal microbiota exacerbates hepatobiliary disease in a murine model of primary sclerosing cholangitis. Hepatology, 2016, 63, 185-196.	7.3	183
65	The enteric microbiome in hepatobiliary health and disease. Liver International, 2016, 36, 480-487.	3.9	28
66	Extracellular vesicles in liver pathobiology: Small particles with big impact. Hepatology, 2016, 64, 2219-2233.	7.3	190
67	Primary Sclerosing Cholangitis. New England Journal of Medicine, 2016, 375, 1161-1170.	27.0	358
68	Polycystic Liver Disease: The Benefits of Targeting cAMP. Clinical Gastroenterology and Hepatology, 2016, 14, 1031-1034.	4.4	15
69	An Octogenarian With Acute Epigastric Pain: More Than Meets the Eye. Gastroenterology, 2016, 150, e5-e6.	1.3	26
70	Microbiomeâ€immune interactions and liver disease. Clinical Liver Disease, 2015, 5, 83-85.	2.1	1
71	MicroRNAs in the Cholangiopathies: Pathogenesis, Diagnosis, and Treatment. Journal of Clinical Medicine, 2015, 4, 1688-1712.	2.4	18
72	MicroRNAs and Benign Biliary Tract Diseases. Seminars in Liver Disease, 2015, 35, 026-035.	3.6	17

#	Article	IF	Citations
73	The Achillesâ€™ heel of senescent cells: from transcriptome to senolytic drugs. Aging Cell, 2015, 14, 644-658.	6.7	1,534
74	Efficacy of 4 Years of Octreotide Long-Acting Release Therapy in Patients With Severe Polycystic Liver Disease. Mayo Clinic Proceedings, 2015, 90, 1030-1037.	3.0	32
75	TGR5 in the Cholangiociliopathies. Digestive Diseases, 2015, 33, 420-425.	1.9	27
76	The Cholangiopathies. Mayo Clinic Proceedings, 2015, 90, 791-800.	3.0	167
77	Ursodeoxycholic acid inhibits hepatic cystogenesis in experimental models of polycystic liver disease. Journal of Hepatology, 2015, 63, 952-961.	3.7	56
78	Characterization of cultured cholangiocytes isolated from livers of patients with primary sclerosing cholangitis. Laboratory Investigation, 2014, 94, 1126-1133.	3.7	85
79	Cholangiocyte senescence by way of N-ras activation is a characteristic of primary sclerosing cholangitis. Hepatology, 2014, 59, 2263-2275.	7.3	194
80	HDAC6 Is Overexpressed in Cystic Cholangiocytes and Its Inhibition Reduces Cystogenesis. American Journal of Pathology, 2014, 184, 600-608.	3.8	43
81	Polycystic liver diseases: advanced insights into the molecular mechanisms. Nature Reviews Gastroenterology and Hepatology, 2014, 11, 750-761.	17.8	80
82	MicroRNAs in Cholangiopathies. Current Pathobiology Reports, 2014, 2, 133-142.	3.4	27
83	Centrosomal Abnormalities Characterize Human and Rodent Cystic Cholangiocytes and Are Associated with Cdc25A Overexpression. American Journal of Pathology, 2014, 184, 110-121.	3.8	19
84	Inhibition of metalloprotease hyperactivity in cystic cholangiocytes halts the development of polycystic liver diseases. Gut, 2014, 63, 1658-1667.	12.1	55
85	Calcium signaling in cilia and ciliary-mediated intracellular calcium signaling: Are they independent or coordinated molecular events?. Hepatology, 2014, 60, 1783-1785.	7.3	9
86	Pasireotide is more effective than octreotide in reducing hepatorenal cystogenesis in rodents with polycystic kidney and liver diseases. Hepatology, 2013, 58, 409-421.	7.3	96
87	G astroenterology 's Editors-in-Chief: Historical and Personal Perspectives of Their Editorships. Gastroenterology, 2013, 145, 16-31.	1.3	2
88	The dynamic biliary epithelia: Molecules, pathways, and disease. Journal of Hepatology, 2013, 58, 575-582.	3.7	130
89	Micro-computed tomography and nuclear magnetic resonance imaging for noninvasive, live-mouse cholangiography. Laboratory Investigation, 2013, 93, 733-743.	3.7	32
90	Release of Luminal Exosomes Contributes to TLR4-Mediated Epithelial Antimicrobial Defense. PLoS Pathogens, 2013, 9, e1003261.	4.7	159

#	Article	IF	Citations
91	Ciliary subcellular localization of TGR5 determines the cholangiocyte functional response to bile acid signaling. American Journal of Physiology - Renal Physiology, 2013, 304, G1013-G1024.	3.4	122
92	HDAC6 Inhibition Restores Ciliary Expression and Decreases Tumor Growth. Cancer Research, 2013, 73, 2259-2270.	0.9	175
93	Physiology of Cholangiocytes. , 2013, 3, 541-565.		179
94	Somatostatin analog therapy for severe polycystic liver disease: results after 2 years. Nephrology Dialysis Transplantation, 2012, 27, 3532-3539.	0.7	120
95	Inhibition of Cdc25A Suppresses Hepato-renal Cystogenesis in Rodent Models of Polycystic Kidney and Liver Disease. Gastroenterology, 2012, 142, 622-633.e4.	1.3	40
96	Physiology of Cholangiocytes. , 2012, , 1531-1557.		3
97	Up-regulation of microRNA 506 leads to decreased Clâ^'/HCO3â^' anion exchanger 2 expression in biliary epithelium of patients with primary biliary cirrhosis. Hepatology, 2012, 56, 687-697.	7.3	199
98	Fibrolamellar hepatocellular carcinoma presenting with budd-chiari syndrome, right atrial thrombus, and pulmonary emboli. Hepatology, 2012, 55, 977-978.	7.3	19
99	TLR4 Promotes Cryptosporidium parvum Clearance in a Mouse Model of Biliary Cryptosporidiosis. Journal of Parasitology, 2011, 97, 813-821.	0.7	32
100	The Role of Cilia in the Regulation of Bile Flow. Digestive Diseases, 2011, 29, 6-12.	1.9	43
101	Patients, cells, and organelles: The intersection of science and serendipity. Hepatology, 2011, 53, 1417-1426.	7.3	1
102	Cholangiocyte N-Ras Protein Mediates Lipopolysaccharide-induced Interleukin 6 Secretion and Proliferation. Journal of Biological Chemistry, 2011, 286, 30352-30360.	3.4	59
103	Randomized Clinical Trial of Long-Acting Somatostatin for Autosomal Dominant Polycystic Kidney and Liver Disease. Journal of the American Society of Nephrology: JASN, 2010, 21, 1052-1061.	6.1	288
104	NFÎºB p50-CCAAT/Enhancer-binding Protein Î² (C/EBPÎ²)-mediated Transcriptional Repression of MicroRNA let-7i following Microbial Infection. Journal of Biological Chemistry, 2010, 285, 216-225.	3.4	97
105	Cholangiocyte Myosin IIB Is Required for Localized Aggregation of Sodium Glucose Cotransporter 1 to Sites ofCryptosporidium parvumCellular Invasion and Facilitates Parasite Internalization. Infection and Immunity, 2010, 78, 2927-2936.	2.2	9
106	Biliary exosomes influence cholangiocyte regulatory mechanisms and proliferation through interaction with primary cilia. American Journal of Physiology - Renal Physiology, 2010, 299, G990-G999.	3.4	234
107	Opisthorchis viverrini excretory/secretory products induce toll-like receptor 4 upregulation and production of interleukin 6 and 8 in cholangiocyte. Parasitology International, 2010, 59, 616-621.	1.3	72
108	Activation of Trpv4 Reduces the Hyperproliferative Phenotype of Cystic Cholangiocytes From an Animal Model of ARPKD. Gastroenterology, 2010, 139, 304-314.e2.	1.3	85

#	Article	IF	Citations
109	Hepato-Renal Pathology in Pkd2/â^' Mice, an Animal Model of Autosomal Dominant Polycystic Kidney Disease. American Journal of Pathology, 2010, 176, 1282-1291.	3.8	31
110	Cholangiocyte Cilia and Basal Bodies. , 2010, , 45-70.		0
111	MicroRNA-513 Regulates B7-H1 Translation and Is Involved in IFN-Î³-Induced B7-H1 Expression in Cholangiocytes. Journal of Immunology, 2009, 182, 1325-1333.	0.8	190
112	Isolation of Primary Cilia for Morphological Analysis. Methods in Cell Biology, 2009, 94, 103-115.	1.1	9
113	HIVâ€1 Tat Protein Suppresses Cholangiocyte Tollâ€Like Receptor 4 Expression and Defense againstCryptosporidium parvum. Journal of Infectious Diseases, 2009, 199, 1195-1204.	4.0	36
114	MicroRNAs in cholangiociliopathies. Cell Cycle, 2009, 8, 1324-1328.	2.6	22
115	The cAMP effectors Epac and protein kinase a (PKA) are involved in the hepatic cystogenesis of an animal model of autosomal recessive polycystic kidney disease (ARPKD). Hepatology, 2009, 49, 160-174.	7.3	110
116	MicroRNA-21 is overexpressed in human cholangiocarcinoma and regulates programmed cell death 4 and tissue inhibitor of metalloproteinase 3. Hepatology, 2009, 49, 1595-1601.	7.3	247
117	Characterization of PKD Protein-Positive Exosome-Like Vesicles. Journal of the American Society of Nephrology: JASN, 2009, 20, 278-288.	6.1	300
118	MicroRNAs: Key Modulators of Posttranscriptional Gene Expression. Gastroenterology, 2009, 136, 17-25.	1.3	95
119	Cholangiociliopathies: genetics, molecular mechanisms and potential therapies. Current Opinion in Gastroenterology, 2009, 25, 265-271.	2.3	83
120	Cholangiocyte primary cilia in liver health and disease. Developmental Dynamics, 2008, 237, 2007-2012.	1.8	142
121	The immunobiology of cholangiocytes. Immunology and Cell Biology, 2008, 86, 497-505.	2.3	74
122	Hepatic Cystogenesis Is Associated with Abnormal Expression and Location of Ion Transporters and Water Channels in an Animal Model of Autosomal Recessive Polycystic Kidney Disease. American Journal of Pathology, 2008, 173, 1637-1646.	3.8	72
123	Cholangiocyte primary cilia are chemosensory organelles that detect biliary nucleotides via P2Y₁₂ purinergic receptors. American Journal of Physiology - Renal Physiology, 2008, 295, G725-G734.	3.4	147
124	MicroRNA15a modulates expression of the cell-cycle regulator Cdc25A and affects hepatic cystogenesis in a rat model of polycystic kidney disease. Journal of Clinical Investigation, 2008, 118, 3714-3724.	8.2	158
125	A Cellular Micro-RNA, let-7i, Regulates Toll-like Receptor 4 Expression and Contributes to Cholangiocyte Immune Responses against Cryptosporidium parvum Infection. Journal of Biological Chemistry, 2007, 282, 28929-28938.	3.4	409
126	Cholangiocyte cilia express TRPV4 and detect changes in luminal tonicity inducing bicarbonate secretion. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 19138-19143.	7.1	186

#	Article	IF	Citations
127	Cholangiocyte biology. Current Opinion in Gastroenterology, 2007, 23, 299-305.	2.3	48
128	Octreotide Inhibits Hepatic Cystogenesis in a Rodent Model of Polycystic Liver Disease by Reducing Cholangiocyte Adenosine 3â€²,5â€²-Cyclic Monophosphate. Gastroenterology, 2007, 132, 1104-1116.	1.3	261
129	Cyclic AMP Regulates Bicarbonate Secretion in Cholangiocytes Through Release of ATP Into Bile. Gastroenterology, 2007, 133, 1592-1602.	1.3	126
130	Cholangiocyte Cilia Detect Changes in Luminal Fluid Flow and Transmit Them Into Intracellular Ca2+ and cAMP Signaling. Gastroenterology, 2006, 131, 911-920.	1.3	259
131	Cytoskeletal and motor proteins facilitate trafficking of AQP1â€containing vesicles in cholangiocytes. Biology of the Cell, 2006, 98, 43-52.	2.0	32
132	Cholangiocyte biology. Current Opinion in Gastroenterology, 2006, 22, 279-287.	2.3	19
133	Cryptosporidium parvum infects human cholangiocytes via sphingolipid-enriched membrane microdomains. Cellular Microbiology, 2006, 8, 1932-1945.	2.1	42
134	Development and characterization of a cholangiocyte cell line from the PCK rat, an animal model of Autosomal Recessive Polycystic Kidney Disease. Laboratory Investigation, 2006, 86, 940-950.	3.7	38
135	Aquaporins in the hepatobiliary system. Hepatology, 2006, 43, S75-S81.	7.3	61
136	Isolation and characterization of lipid microdomains from apical and basolateral plasma membranes of rat hepatocytes. Hepatology, 2006, 43, 287-296.	7.3	75
137	Polycystic liver disease: New insights into disease pathogenesis. Hepatology, 2006, 43, 906-908.	7.3	35
138	Primary sclerosing cholangitis: Summary of a workshop. Hepatology, 2006, 44, 746-764.	7.3	235
139	Engineered measles virus as a novel oncolytic viral therapy system for hepatocellular carcinoma. Hepatology, 2006, 44, 1465-1477.	7.3	110
140	Proteolytic Cleavage and Nuclear Translocation of Fibrocystin Is Regulated by Intracellular Ca2+ and Activation of Protein Kinase C. Journal of Biological Chemistry, 2006, 281, 34357-34364.	3.4	85
141	Isolation and characterization of cholangiocyte primary cilia. American Journal of Physiology - Renal Physiology, 2006, 291, G500-G509.	3.4	95
142	Physiology of Cholangiocytes. , 2006, , 1505-1533.		4
143	Cholangiocyte biology. Current Opinion in Gastroenterology, 2005, 21, 337-343.	2.3	3
144	Aquaporin-8 Is Involved in Water Transport in Isolated Superficial Colonocytes from Rat Proximal Colon. Journal of Nutrition, 2005, 135, 2329-2336.	2.9	45

#	Article	IF	Citations
145	Multiple TLRs Are Expressed in Human Cholangiocytes and Mediate Host Epithelial Defense Responses to Cryptosporidium parvum via Activation of NF-ÎºB. Journal of Immunology, 2005, 175, 7447-7456.	0.8	199
146	Regulated vesicle trafficking of membrane transporters in hepatic epithelia. Journal of Hepatology, 2005, 42, 592-603.	3.7	18
147	Localized glucose and water influx facilitates Cryptosporidium parvum cellular invasion by means of modulation of host-cell membrane protrusion. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 6338-6343.	7.1	84
148	Apical Organelle Discharge by Cryptosporidium parvum Is Temperature, Cytoskeleton, and Intracellular Calcium Dependent and Required for Host Cell Invasion. Infection and Immunity, 2004, 72, 6806-6816.	2.2	77
149	Phosphatidylinositol 3-Kinase and Frabin Mediate Cryptosporidium parvum Cellular Invasion via Activation of Cdc42. Journal of Biological Chemistry, 2004, 279, 31671-31678.	3.4	65
150	Cdc42 and the Actin-Related Protein/Neural Wiskott-Aldrich Syndrome Protein Network Mediate Cellular Invasion by Cryptosporidium parvum. Infection and Immunity, 2004, 72, 3011-3021.	2.2	52
151	AQP4 transfected into mouse cholangiocytes promotes water transport in biliary epithelia. Hepatology, 2004, 39, 109-116.	7.3	28
152	The cholangiopathies: Disorders of biliary epithelia. Gastroenterology, 2004, 127, 1565-1577.	1.3	326
153	Biliary Dysgenesis in the PCK Rat, an Orthologous Model of Autosomal Recessive Polycystic Kidney Disease. American Journal of Pathology, 2004, 165, 1719-1730.	3.8	105
154	Rat hepatocyte aquaporin-8 water channels are down-regulated in extrahepatic cholestasis. Hepatology, 2003, 37, 1026-1033.	7.3	66
155	Glucagon induces the plasma membrane insertion of functional aquaporin-8 water channels in isolated rat hepatocytes. Hepatology, 2003, 37, 1435-1441.	7.3	76
156	Defects in cholangiocyte fibrocystin expression and ciliary structure in the PCK rat1 1The authors thank Dr. Torra for supplying ARPKD tissue.. Gastroenterology, 2003, 125, 1303-1310.	1.3	194
157	Cryptosporidium parvum invasion of biliary epithelia requires host cell tyrosine phosphorylation of cortactin via c-Src. Gastroenterology, 2003, 125, 216-228.	1.3	75
158	Cytokine-stimulated nitric oxide production inhibits adenylyl cyclase and cAMP-dependent secretion in cholangiocytes. Gastroenterology, 2003, 124, 737-753.	1.3	129
159	Hepatic Artery and Portal Vein Remodeling in Rat Liver. American Journal of Pathology, 2003, 162, 1175-1182.	3.8	52
160	Agonist-induced Coordinated Trafficking of Functionally Related Transport Proteins for Water and Ions in Cholangiocytes. Journal of Biological Chemistry, 2003, 278, 20413-20419.	3.4	108
161	Specific Inhibition of AQP1 Water Channels in Isolated Rat Intrahepatic Bile Duct Units by Small Interfering RNAs. Journal of Biological Chemistry, 2003, 278, 6268-6274.	3.4	56
162	Water Transporting Properties of Hepatocyte Basolateral and Canalicular Plasma Membrane Domains. Journal of Biological Chemistry, 2003, 278, 43157-43162.	3.4	63

#	Article	IF	Citations
163	Cholangiocyte biology. Current Opinion in Gastroenterology, 2003, 19, 264-269.	2.3	0
164	Somatostatin stimulates ductal bile absorption and inhibits ductal bile secretion in mice via SSTR2 on cholangiocytes. American Journal of Physiology - Cell Physiology, 2003, 284, C1205-C1214.	4.6	62
165	Expression and Localization of Aquaporin Water Channels in Rat Hepatocytes. Journal of Biological Chemistry, 2002, 277, 22710-22717.	3.4	131
166	Cholangiocyte biology. Current Opinion in Gastroenterology, 2002, 18, 360-365.	2.3	2
167	Water transport by epithelia of the digestive tract. Gastroenterology, 2002, 122, 545-562.	1.3	130
168	Cryptosporidiosis. New England Journal of Medicine, 2002, 346, 1723-1731.	27.0	451
169	Channel-mediated water movement across enclosed or perfused mouse intrahepatic bile duct units. American Journal of Physiology - Cell Physiology, 2002, 283, C338-C346.	4.6	36
170	Intrahepatic bile ducts transport water in response to absorbed glucose. American Journal of Physiology - Cell Physiology, 2002, 283, C785-C791.	4.6	51
171	The pathobiology of biliary epithelia. Hepatology, 2002, 35, 1256-1268.	7.3	135
172	Regulation of Ca2+ signaling in rat bile duct epithelia by inositol 1,4,5-trisphosphate receptor isoforms. Hepatology, 2002, 36, 284-296.	7.3	79
173	Experimental models to study cholangiocyte biology. World Journal of Gastroenterology, 2002, 8, 1.	3.3	11
174	Nitric oxideâ€“mediated inhibition of DNA repair potentiates oxidative DNA damage in cholangiocytes. Gastroenterology, 2001, 120, 190-199.	1.3	212
175	Quantitative Assessment of the Rat Intrahepatic Biliary System by Three-Dimensional Reconstruction. American Journal of Pathology, 2001, 158, 2079-2088.	3.8	59
176	Cryptosporidium parvum activates nuclear factor ÎºB in biliary epithelia preventing epithelial cell apoptosis. Gastroenterology, 2001, 120, 1774-1783.	1.3	135
177	Nitric oxide in gastrointestinal epithelial cell carcinogenesis: linking inflammation to oncogenesis. American Journal of Physiology - Renal Physiology, 2001, 281, G626-G634.	3.4	236
178	Polarized expression and function of P2Y ATP receptors in rat bile duct epithelia. American Journal of Physiology - Renal Physiology, 2001, 281, G1059-G1067.	3.4	85
179	Stimulation of ATP secretion in the liver by therapeutic bile acids. Biochemical Journal, 2001, 358, 1-5.	3.7	67
180	Water movement across rat bile duct units is transcellular and channel-mediated. Hepatology, 2001, 34, 456-463.	7.3	31

#	Article	IF	Citations
181	The Water Channel Aquaporin-8 Is Mainly Intracellular in Rat Hepatocytes, and Its Plasma Membrane Insertion Is Stimulated by Cyclic AMP. Journal of Biological Chemistry, 2001, 276, 12147-12152.	3.4	177
182	Expression of aquaporin-4 water channels in rat cholangiocytes. Hepatology, 2000, 31, 1313-1317.	7.3	54
183	Current therapies and clinical controversies in the management of primary sclerosing cholangitis. Current Gastroenterology Reports, 2000, 2, 99-103.	2.5	7
184	The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis. American Journal of Gastroenterology, 2000, 95, 204-207.	0.4	376
185	Perfused rat intrahepatic bile ducts secrete and absorb water, solute, and ions. Gastroenterology, 2000, 119, 1672-1680.	1.3	45
186	Mechanisms of attachment and internalization of Cryptosporidium parvum to biliary and intestinal epithelial cells. Gastroenterology, 2000, 118, 368-379.	1.3	106
187	Secretin induces the apical insertion of aquaporin-1 water channels in rat cholangiocytes. American Journal of Physiology - Renal Physiology, 1999, 276, G280-G286.	3.4	75
188	Oral nicotine in treatment of primary sclerosing cholangitis: a pilot study. Digestive Diseases and Sciences, 1999, 44, 602-607.	2.3	70
189	Recurrence of primary sclerosing cholangitis following liver transplantation. Hepatology, 1999, 29, 1050-1056.	7.3	344
190	The relative role of the child-pugh classification and the mayo natural history model in the assessment of survival in patients with primary sclerosing cholangitis. Hepatology, 1999, 29, 1643-1648.	7.3	124
191	Long-term results of patients undergoing liver transplantation for primary sclerosing cholangitis. Hepatology, 1999, 30, 1121-1127.	7.3	329
192	Biliary Tract Cancers. New England Journal of Medicine, 1999, 341, 1368-1378.	27.0	933
193	Anatomy of the human biliary system studied by quantitative computer-aided three-dimensional imaging techniques. Hepatology, 1998, 27, 893-899.	7.3	93
194	Cryptosporidium parvum is cytopathic for cultured human biliary epithelia via an apoptotic mechanism. Hepatology, 1998, 28, 906-913.	7.3	102
195	Purinergic regulation of acid/base transport in human and rat biliary epithelial cell lines. Hepatology, 1998, 28, 914-920.	7.3	48
196	Characterization and growth regulation of a rat intrahepatic bile duct epithelial cell line under hormonally defined, serum-free conditions. In Vitro Cellular and Developmental Biology - Animal, 1998, 34, 704-710.	1.5	24
197	Heterogeneity of the proliferative capacity of rat cholangiocytes after bile duct ligation. American Journal of Physiology - Renal Physiology, 1998, 274, G767-G775.	3.4	119
198	Glutathione depletion is associated with decreased Bcl-2 expression and increased apoptosis in cholangiocytes. American Journal of Physiology - Renal Physiology, 1998, 275, G749-G757.	3.4	60

#	Article	IF	Citations
199	Functional polarity of Na⁺/H⁺and Cl^{â^'}/ HCO 3 â^' exchangers in a rat cholangiocyte cell line. American Journal of Physiology - Renal Physiology, 1998, 275, G1236-G1245.	3.4	30
200	Interactions Between Chronic Liver Disease and Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 1997, 3, 288-302.	1.9	54
201	Secretin Promotes Osmotic Water Transport in Rat Cholangiocytes by Increasing Aquaporin-1 Water Channels in Plasma Membrane. Journal of Biological Chemistry, 1997, 272, 12984-12988.	3.4	178
202	Regulation of biliary secretion through apical purinergic receptors in cultured rat cholangiocytes. American Journal of Physiology - Renal Physiology, 1997, 273, G1108-G1117.	3.4	41
203	Aquaporin water channels in liver: Their significance in bile formation. Hepatology, 1997, 26, 1081-1084.	7.3	46
204	Interactions between chronic liver disease and inflammatory bowel disease. Inflammatory Bowel Diseases, 1997, 3, 288-302.	1.9	58
205	Characterization of Apical and Basolateral Plasma Membrane Domains Derived from Cultured Rat Cholangiocytes. Analytical Biochemistry, 1997, 254, 192-199.	2.4	32
206	Rat Hepatocytes Transport Water Mainly via a Non-channel-mediated Pathway. Journal of Biological Chemistry, 1996, 271, 6702-6707.	3.4	45
207	Solute and Water Transport Pathways in Cholangiocytes. Seminars in Liver Disease, 1996, 16, 221-229.	3.6	32
208	Quantitative importance of biliary excretion to the turnover of hepatic lysosomal enzymes. Hepatology, 1995, 22, 262-266.	7.3	9
209	Dynamic measurements of the acute and chronic effects of lysosomotropic agents on hepatocyte lysosomal pH using flow cytometry. Hepatology, 1995, 22, 1519-1526.	7.3	30
210	Isolation and characterization of rat cholangiocyte vesicles enriched in apical or basolateral plasma membrane domains. Biochemistry, 1995, 34, 15436-15443.	2.5	67
211	Human cholangiocarcinomas express somatostatin receptors and respond to somatostatin with growth inhibition. Gastroenterology, 1995, 108, 1908-1916.	1.3	55
212	Recent advances in the isolation of liver cells. Hepatology, 1994, 20, 494-514.	7.3	160
213	Recent advances in the isolation of liver cells. Hepatology, 1994, 20, 494-514.	7.3	15
214	Diagnostic Role of Serum CA 19-9 for Cholangiocarcinoma in Patients With Primary Sclerosing Cholangitis. Mayo Clinic Proceedings, 1993, 68, 874-879.	3.0	207
215	Cholangiocarcinoma Complicating Primary Sclerosing Cholangitis. Annals of Surgery, 1991, 213, 21-25.	4.2	337
216	The metabolic bone disease of primary sclerosing cholangitis. Hepatology, 1991, 14, 257-261.	7.3	115

#	Article	IF	Citations
217	The metabolic bone disease of primary sclerosing cholangitis. Hepatology, 1991, 14, 257-261.	7.3	7
218	Morphologic Demonstration of Receptor-Mediated Endocytosis of Epidermal Growth Factor by Isolated Bile Duct Epithelial Cells. Gastroenterology, 1990, 98, 1284-1291.	1.3	38
219	Physicochemical determinants in hepatic extraction of small peptides. Hepatology, 1990, 12, 76-82.	7.3	29
220	Lack of metabolic effects of cholecystokinin on hepatocytes. Hepatology, 1990, 12, 301-305.	7.3	11
221	Primary sclerosing cholangitis: Natural history, prognostic factors and survival analysis. Hepatology, 1989, 10, 430-436.	7.3	622
222	The liver and intracellular digestion: How liver cells eat!. Hepatology, 1989, 10, 877-886.	7.3	24
223	Isolation and morphologic characterization of bile duct epithelial cells from normal rat liver. Gastroenterology, 1989, 97, 1236-1247.	1.3	196
224	Effect of Proctocolectomy for Chronic Ulcerative Colitis on the Natural History of Primary Sclerosing Cholangitis. Gastroenterology, 1989, 96, 790-794.	1.3	118
225	Pharmacologic perturbation of rat liver lysosomes: Effects on release of lysosomal enzymes and of lipids into bile. Gastroenterology, 1988, 95, 1088-1098.	1.3	25
226	Prospective trial of penicillamine in primary sclerosing cholangitis. Gastroenterology, 1988, 95, 1036-1042.	1.3	168
227	Enhanced autoreactivity of T-lymphocytes in primary sclerosing cholangitis. Hepatology, 1987, 7, 884-888.	7.3	60
228	Hepatic extraction of renin: Quantitation and characterization in the isolated perfused rat liver. Hepatology, 1987, 7, 1254-1261.	7.3	13
229	Peristomal varices after proctocolectomy in patients with primary sclerosing cholangitis. Gastroenterology, 1986, 90, 316-322.	1.3	147
230	The isolated perfused rat liver: Conceptual and practical considerations. Hepatology, 1986, 6, 511-517.	7.3	264
231	Intrahepatic cholangiectases and large-duct obliteration in primary sclerosing cholangitis. Hepatology, 1986, 6, 560-568.	7.3	90
232	Abnormalities in tests of copper metabolism in primary sclerosing cholangitis. Gastroenterology, 1985, 89, 272-278.	1.3	80
233	Comparison of the Clinicopathologic Features of Primary Sclerosing Chol-angitis and Primary Biliary Cirrhosis. Gastroenterology, 1985, 88, 108-114.	1.3	205
234	Manifestations of nonsuppurative cholangitis in chronic hepatobiliary diseases: morphologic spectrum, clinical correlations and terminology. Liver, 1984, 4, 105-116.	0.1	113

#	Article	IF	Citations
235	Effect of Chloroquine on the Form and Function of Hepatocyte Lysosomes Morphologic Modifications and Physiologic Alterations Related to the Biliary Excretion of Lipids and Proteins. Gastroenterology, 1983, 85, 1146-1153.	1.3	37
236	Elevated Circulating Immune Complexes in Primary Sclerosing Cholangitis. Hepatology, 1983, 3, 150-154.	7.3	131
237	Triton WR-1339, A Lysosomotropic Compound, Is Excreted into Bile and Alters the Biliary Excretion of Lysosomal Enzymes and Lipids. Hepatology, 1982, 2, 209S-215S.	7.3	36
238	Morphologic features of chronic hepatitis associated with primary sclerosing cholangitis and chronic ulcerative colitis. Hepatology, 1981, 1, 632-640.	7.3	325
239	Clinicopathologic features of the syndrome of primary sclerosing cholangitis. Gastroenterology, 1980, 79, 200-206.	1.3	541
240	Coordinate Secretion of Acid Hydrolases in Rat Bile. Journal of Clinical Investigation, 1979, 64, 948-954.	8.2	104
241	Effect of Deoxycholic Acid Ingestion on Bile Acid Metabolism and Biliary Lipid Secretion in Normal Subjects. Gastroenterology, 1977, 72, 132-140.	1.3	129
242	Abnormalities of Chemical Tests for Copper Metabolism in Chronic Active Liver Disease: Differentiation from Wilson's Disease. Gastroenterology, 1976, 70, 653-655.	1.3	67
243	Validity and Sensitivity of an Intravenous Bile Acid Tolerance Test in Patients with Liver Disease. New England Journal of Medicine, 1975, 292, 1209-1214.	27.0	88